Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy.
Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti G, Orsi G, Veronesi E, Horwitz EM, Dominici M. Rossignoli F, et al. Among authors: orsi g. Cancer Gene Ther. 2019 Feb;26(1-2):11-16. doi: 10.1038/s41417-018-0034-1. Epub 2018 Jun 29. Cancer Gene Ther. 2019. PMID: 29955091 Free PMC article.
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. Orsi G, et al. Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. Oncotarget. 2017. PMID: 28415563 Free PMC article.
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.
Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Spano C, et al. Among authors: orsi g. Sci Rep. 2019 Feb 11;9(1):1788. doi: 10.1038/s41598-018-37433-6. Sci Rep. 2019. PMID: 30742129 Free PMC article.
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma.
Rossignoli F, Spano C, Grisendi G, Foppiani EM, Golinelli G, Mastrolia I, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Veronesi E, Medici G, Petocchi B, Pinelli M, Horwitz EM, Conte P, Dominici M. Rossignoli F, et al. Among authors: orsi g. Theranostics. 2019 Jan 1;9(2):436-448. doi: 10.7150/thno.27576. eCollection 2019. Theranostics. 2019. PMID: 30809285 Free PMC article.
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: orsi g. Clin Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. Clin Colorectal Cancer. 2020. PMID: 32192883
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib.
Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini A. Marisi G, et al. Among authors: orsi g. Cancers (Basel). 2019 Jul 20;11(7):1023. doi: 10.3390/cancers11071023. Cancers (Basel). 2019. PMID: 31330833 Free PMC article.
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort.
Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, Rizzato MD, Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G, Biason P, Lonardi S, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: orsi g. Gastrointest Tumors. 2019 Oct;6(3-4):71-80. doi: 10.1159/000501593. Epub 2019 Aug 20. Gastrointest Tumors. 2019. PMID: 31768351 Free PMC article.
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.
Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Rovesti G, et al. Among authors: orsi g. Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714. Epub 2019 Sep 12. Gastrointest Tumors. 2019. PMID: 31768353 Free PMC article.
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.
Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Casadei-Gardini A, et al. Among authors: orsi g. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi: 10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. Clin Cancer Res. 2020. PMID: 32371540
417 results